How Has the Interstitial Lung Disease Market Evolved Historically and What is its Current Size?
The interstitial lung disease market has seen considerable growth due to a variety of factors.
• The market size of interstitial lung disease has seen a robust growth recently. It is projected to expand from $1.97 billion in 2024 to $2.11 billion in 2025, with a compound annual growth rate (CAGR) of 7.2%.
Factors contributing to the growth in the past have been increased awareness and advancements in diagnostics, therapies modulating the immune system, respiratory rehabilitation programs, and the introduction of multidisciplinary care teams.
What Does Future Hold for The Interstitial Lung Disease Market By 2029?
The interstitial lung disease market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market size for interstitial lung disease is projected to significantly expand, with expectations to reach a worth of $2.85 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%.
The growth anticipated within the projected timeline is mainly due to factors such as precision medicine, the introduction of new drugs, regenerative medicine, along with telehealth and remote monitoring. Key trends that will mark this period of growth include advancements in imaging technology, the use of artificial intelligence in imaging, differentiation of fibrosis subtypes, and the provision of supportive care services.
What Are The Primary Growth Drivers In The Interstitial Lung Disease Market?
The surge in allergic conditions is anticipated to fuel the expansion of the interstitial lung disease market. Allergies are characterized by the immune system's exaggerated response to an allergen, often an innocuous substance. One particular form of interstitial lung disease (ILD) could occur as a result of allergic reactions, specifically hypersensitivity pneumonitis, which causes allergic responses in the body. Reportedly in November 2023, the National Asthma Council, an Australian non-profit organization dedicated to improving asthma care and management, disclosed 467 asthma-related fatalities in 2022, with 299 females and 168 males. This marked an increase from the 355 deaths in 2021. Consequently, the upswing in allergic diseases is propelling the skin health foods market's growth, reinforcing the role allergic conditions play in driving the interstitial lung disease market's expansion. An uptick in autoimmune disorders is projected to bolster the interstitial lung disease market's progress. Autoimmune disorders are health issues when the immune system mistakenly attacks the body's normal tissues and cells. The increasing occurrence of these conditions promotes demand for healthcare services related to ILD, enhances research and development, and cultivates advancements in treatment and patient care. As of September 2023, the Institute for Health Metrics and Evaluation, a US-based global health research institute, predicts that rheumatoid arthritis cases worldwide are set to rise to 31.7 million by 2050, marking a considerable surge. Consequently, an increase in autoimmune disorders is driving the growth of the interstitial lung disease market.
What Is The Segmentation Of The Global Interstitial Lung Disease Market?
The interstitial lung disease market covered in this report is segmented –
1) By Drug Type: Oral Corticosteroids, Immune Suppressing, Anti-Fibrotic Medication, Other Drugs
2) By Disease Type: Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonitis, Hypersensitivity Pneumonitis, Cryptogenic Organizing Pneumonia (COP), Sarcoidosis, Acute Interstitial Pneumonitis
3) By Application: Adults, Children
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Oral Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone
2) By Immune Suppressing: Azathioprine, Methotrexate, Mycophenolate Mofetil
3) By Anti-Fibrotic Medication: Pirfenidone, Nintedanib
4) By Other Drugs: Antioxidants, Anticoagulants, Other Novel Therapies
Pre-Book The Interstitial Lung Disease Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Interstitial Lung Disease Market?
In the interstitial lung disease market, dominant companies are riding the trend of launching products such as innovative treatments for several interstitial lung illnesses, including idiopathic pulmonary fibrosis (IPF). IPF is a long-term lung ailment characterized by lung tissue scarring, resulting in breathing problems and a decline in oxygen transfer. For example, C.H. Boehringer Sohn AG & Co. KG, a biopharmaceutical firm based in Germany, gained FDA approval in February 2024 for BI 1015550 Therapy for treating Idiopathic Pulmonary Fibrosis. BI 1015550 is an experimental oral treatment that suppresses phosphodiesterase 4B (PDE4B), exerting antifibrotic and anti-inflammatory effects to retard the deterioration of lung function in IPF cases.
Who Are the Key Players In The Interstitial Lung Disease Market?
Major companies operating in the interstitial lung disease market are:
• Roche Laboratories Inc.
• Merck & Co. Inc.
• Bayer AG
• Novartis Pharmaceuticals Corporation
• The Bristol-Myers Squibb Company
• Amgen Inc.
• Boehringer Ingelheim
• Siemens Healthineers
• Koninklijke Philips N.V.
• Teva Pharmaceuticals USA Inc.
• AstraZeneca PLC
• Horizon Pharma USA Inc.
• Genentech Inc.
• Amneal Pharmaceuticals LLC
• Fujirebio Diagnostics Inc.
• Insmed Inc.
• VIDA Diagnostics Inc.
• EmphyCorp Inc.
• Verseau Therapeutics
• Regend Therapeutics Co.
• LTT Bio-Pharma Co. Ltd.
• Galecto Biotech
• Pulmatrix Inc.
• PureTech Health PLC
• Pneuma Respiratory Inc.
• Bellerophon Therapeutics Inc.
• MediciNova Inc.
• Altavant Sciences Inc.
• Verona Pharma plc.
What Are The Regional Insights Into The Interstitial Lung Disease Market?
North America was the largest region in the interstitial lung disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interstitial lung disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
